Indicative listing context
How to Buy OpenEvidence Shares Before IPO: Private-Market Access
Just researching? Get free OpenEvidence mark alerts by email
Because OpenEvidence is privately held, its shares cannot be purchased through a standard public brokerage ticker before an IPO. Business Insider reported on September 24, 2026 that clinical decision-support AI platform OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz at a $15 billion valuation (up from $12 billion in January 2026), alongside a global clinical AI partnership with Anthropic reported by Reuters on September 22, 2026. Pre-IPO exposure typically occurs via negotiated secondary share transfers or special-purpose vehicles (SPVs), subject to transfer restrictions and review.
Educational pre-IPO guide.
Private-share data lens
Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.
| Stage | Date | Valuation / price signal | Why it matters |
|---|---|---|---|
| Seed / early | Private | Not reliably public | Do not invent a seed price when the source set is thin. |
| Growth rounds | Private | Company and market sources vary | Use public sources and official company releases. |
| Segmara listing | Current | No indicative price yet | Indicative reference only, not a quote or an offer. |
| IPO status | Current | No public ticker shown here | Watch official company releases and the free Segmara IPO calendar. |
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
| Metric | Value | Context |
|---|---|---|
| Canonical route | /blog/how-to-buy-openevidence-shares-before-ipo | Stable URL path for AI and search extraction. |
| Article title | How to Buy OpenEvidence Shares Before IPO: Private-Market Access | Main page topic. |
| Attached public sources | 3 | Number of citation links rendered at the bottom of the article. |
| Segmara listed companies | 148 | Live private-company listings in the public catalogue. |
| Priced listings | 37 | Catalogue listings with visible indicative or direct marks. |
| Listings without an indicative price | 111 | Catalogue listings where a public price is intentionally not invented. |
| Company | OpenEvidence | Named company covered by this page. |
| Symbol label | OPEV | Segmara display symbol; not a public stock ticker unless separately stated. |
| Sector | Healthcare AI | Catalogue sector used for comparison and internal linking. |
| Listing structure | Not available | How the listing is categorized on Segmara. |
| Segmara mark | No indicative price yet | Visible listing mark, or no indicative price yet. |
| Sector peer count | 2 | Number of live Segmara listings in Healthcare AI. |
| Structure peer count | 111 | Number of live Segmara listings categorized as Not available. |
Data fingerprint chart
| Stage | Timing | Price / valuation signal | Interpretation |
|---|---|---|---|
| Formation | Private | Early ownership | The first value creation happens before ordinary public-market access. |
| Growth rounds | Private | Institutional repricing | Later rounds and tenders create the price history buyers study. |
| Segmara listing | Current | No indicative price yet | Indicative reference only, not a quote or an offer. |
| Exit path | Future | IPO, tender, acquisition, or continued private status | Liquidity timing remains company-specific. |
| Chart metric | Score | Interpretation |
|---|
Analytical lens
Search intent
Searches like 'How to Buy OpenEvidence Shares Before IPO: Private-Market Access' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
What counts as a listing step
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara role
It also publishes dated indicative reference marks across 140+ private companies. Nothing on this page is investment advice.
Key takeaways
- Direct secondary share transfers and SPV allocations are the standard private-market routes before a OpenEvidence public listing.
- Business Insider reported on September 24, 2026 that clinical decision-support AI platform OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz at a $15 billion valuation (up from $12 billion in January 2026), alongside a global clinical AI partnership with Anthropic reported by Reuters on September 22, 2026.
Risk notes
- Private secondary shares carry multi-year illiquidity, fee layers, and right-of-first-refusal or issuer transfer restrictions.
- Avoid unverified social-media token offers claiming to represent OpenEvidence common equity.
Public source links
- OpenEvidence Raises $250 Million From Hospital Systems, Andreessen Horowitz at $15 Billion Valuation (Business Insider, September 24, 2026)
- Startups to Watch: IPO, AI Chips, and Fintech in 2026 (Crunchbase News, September 2, 2026)
- Anthropic, OpenEvidence Partner to Bring Medical AI Worldwide (Reuters, September 22, 2026)
Related reviews
- When Will OpenEvidence IPO? A $15 Billion Valuation, Still No Filing
- OpenEvidence Stock Price (Pre-IPO)
- How to Buy Abridge Shares Before IPO: Private-Market Access Basics
- How to Buy Aspen Neuroscience Shares Before IPO: Private-Market Access
- How to Buy City Therapeutics Shares Before IPO: Private-Market Access
- How to Buy Iambic Therapeutics Shares Before IPO: Private-Market Access
Questions
Can retail stock apps buy OpenEvidence shares right now?
No. Standard public stock brokerages only carry publicly listed tickers, and OpenEvidence has not completed an initial public offering.
Where can I track OpenEvidence's IPO timeline?
Read Segmara's OpenEvidence filing tracker at /blog/when-will-openevidence-ipo or subscribe free by email on this page for weekday filing updates.